With close monitoring, the discontinuation of eculizumab is safe in the majority of patients with atypical hemolytic uremic syndrome. Discontinuation of the terminal complement inhibitor eculizumab in ...

Researchers analyzed BTH definition, frequency, and severity across phase 3 clinical trials with terminal complement inhibitors (ravulizumab and crovalimab) and upstream complement inhibitors ...

Gefurulimab showed significant improvements in MG-ADL scores in the phase 3 PREVAIL study for anti-AChR antibody-positive gMG patients. The treatment was well tolerated, with a safety profile ...

The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Complement C5 Inhibitors & C5 Receptor Antagonists" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A research team at the Medical University of South Carolina reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that ...

Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor (FcRn) inhibitors, offer a new treatment paradigm, though challenges remain. "An ...

New York, USA, April 30, 2026 (GLOBE NEWSWIRE)-- Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | ...